New rapid diagnostic tests for Neisseria meningitidis serogroups A, W135, C, and Y.
Suzanne Chanteau, Sylvie Dartevelle, Ali Elhadj Mahamane, Saacou Djibo, Pascal Boisier, Farida Nato

To cite this version:

New Rapid Diagnostic Tests for *Neisseria meningitidis* Serogroups A, W135, C, and Y

Suzanne Chanteau1,2*, Sylvie Dartevelle1, Ali Elhadj Mahamane2, Saacou Djibo2, Pascal Boisier2, Farida Nato1

1 Institut Pasteur, Plateforme Technologique PT5, Paris, France, 2 CERMES, National Reference Center for Meningitis, Ministry of Health, Réseau International Instituts Pasteur, Niamey, Niger

**ABSTRACT**

**Background**

Outbreaks of meningococcal meningitis (meningitis caused by *Neisseria meningitidis*) are a major public health concern in the African “meningitis belt,” which includes 21 countries from Senegal to Ethiopia. Of the several species that can cause meningitis, *N. meningitidis* is the most important cause of epidemics in this region. In choosing the appropriate vaccine, accurate *N. meningitidis* serogroup determination is key. To this end, we developed and evaluated two duplex rapid diagnostic tests (RDTs) for detecting *N. meningitidis* polysaccharide (PS) antigens of several important serogroups.

**Methods and Findings**

Mouse monoclonal IgG antibodies against *N. meningitidis* PS A, W135/Y, Y, and C were used to develop two immunochromatography duplex RDTs, RDT1 (to detect serogroups A and W135/Y) and RDT2 (to detect serogroups C and Y). Standards for Reporting of Diagnostic Accuracy criteria were used to determine diagnostic accuracy of RDTs on reference strains and cerebrospinal fluid (CSF) samples using culture and PCR, respectively, as reference tests. The cutoffs were 10⁵ cfu/ml for reference strains and 1 ng/ml for PS. Sensitivities and specificities were 100% for reference strains, and 93.8%–100% for CSF serogroups A, W135, and Y in CSF. For CSF serogroup A, the positive and negative likelihood ratios (+ 95% confidence intervals [CIs]) were 31.867 (16.1–63.1) and 0.065 (0.04–0.104), respectively, and the diagnostic odds ratio (+ 95% CI) was 492.9 (207.2–1,172.5). For CSF serogroups W135 and Y, the positive likelihood ratio was 159.6 (51.7–493.3) Both RDTs were equally reliable at 25°C and 45°C.

**Conclusions**

These RDTs are important new bedside diagnostic tools for surveillance of meningococcus serogroups A and W135, the two serogroups that are responsible for major epidemics in Africa.

---

*To whom correspondence should be addressed. E-mail: schanteau@cermes.org*
Introduction

It is estimated that annually over one million cases of meningitis are caused by three bacterial species: *Neisseria meningitidis* (also termed meningococci, the cause of meningococcal meningitis or disease), *Streptococcus pneumoniae*, and *Haemophilus influenzae* b [1]. Together, these organisms cause substantial morbidity and mortality globally. *N. meningitidis* is the cause of epidemic meningitis associated with high mortality worldwide, but more than 50% of all of these meningococcal meningitis cases are reported from sub-Saharan Africa’s “meningitis belt,” which extends from Senegal to Ethiopia and includes 21 countries with a total at-risk population of 250 million [1]. Severe annual outbreaks of meningococcal meningitis are reported in this region, and incidence of the disease may be as high as 1,000 per 100,000 inhabitants [3–5]. Outbreaks occurring during the past ten years (1995–2004) have resulted in almost 700,000 cases and 60,000 deaths [5].

*N. meningitidis* polysaccharide (PS) serogroup A is responsible for major epidemics in Africa, but the recent change in epidemiological pattern due to the emergence of serogroup W135 as an epidemic strain is a cause of particular concern [6–8]. The WHO strategy for controlling epidemic meningococcal disease in this region is based on (i) early and accurate detection and (ii) rapid implementation of mass vaccination using an appropriate polysaccharide (PS) vaccine [9]. However, the response to epidemic meningococcal disease in Africa is hindered by delays in (or even the lack of) identification of the causal agent and by the scarcity and high cost of polyclonal vaccines. Decision-makers at country level in the meningitis belt need to make use of the best epidemiological and laboratory evidence for choosing the most appropriate vaccine. The implementation of alert and epidemic thresholds and of a decisional tree, based on reliable identification of the aetiological agent for selection of the most appropriate vaccine, is recommended [1,10].

The gold standard diagnostics for meningococci are the classic culture with subsequent identification of serogroup using specific antisera and the multiplex PCR method [11]. In the sub-Saharan countries, neither of these two tests is available outside the capitals, large cities, or reference laboratory settings [12]. The old nonculture tests (leucocyte cell count and Gram stain microscopy), although rapid and cheap, cannot identify the serogroup responsible for a given outbreak to guide the choice of vaccine. Currently, latex agglutination tests (LATs) are most widely used to identify meningococcal PS serogroups in the cerebrospinal fluid (CSF) of patients. The Pastorex (Bio-Rad) kit for detecting serogroup A, B, C, and W135/Y has been evaluated for serogroup A and W135 under reference laboratory conditions [13] and in a district laboratory in Niger [14]. The sensitivity and specificity are good, ranging from 84.9% to 88% and from 93% to 97.4%, respectively. This kit does not, however, differentiate between serogroups W135 and Y, and its performance under field conditions lacking basic laboratory equipment is not known. Furthermore, this kit requires cold storage, and its high cost does not allow its use in every district or health care centre. Together these difficulties explain the consistent failure of outbreak aetiology identification and the lack of proper case management (resulting in inadequate antimicrobial treatment), which are main causes of death due to meningococcal disease.

In view of this situation, we therefore aimed to develop and evaluate the diagnostic accuracy of easy-to-perform rapid diagnostic tests (RDTs) for the specific and sensitive detection of meningococcal PS serogroup antigens that can be used in resource-poor countries, especially near rural populations and at the patient’s bedside.

Methods

Standard Diagnostic Methods

Culture and PCR were used as gold-standard diagnostic methods. They were performed by two trained technicians according to reference techniques routinely used at the CERMES (National Reference Centre for Meningitis, Niamey, Niger) [12].

For culture, CSF specimens were drawn from clinically suspected cases of meningitis according to the national guidelines of the Ministry of Health. The specimens were cultured on blood agar and chocolate agar (at 37 °C with 5% CO₂) and the serogroups of the *N. meningitidis* isolates were determined by agglutination with serogroup-specific antisera (Bio-Rad, Marnes-la-Coquette, France, and DIFCO, Detroit, Michigan, United States).

Multiplex PCR was performed on freeze-boiled CSF samples to amplify the *crgA* gene of *N. meningitidis* [11], the *lytA* gene of *S. pneumoniae* [15], and the *bexA* gene of *H. influenzae* [16]. For genogrouping of meningococcus-positive specimens, a second PCR was performed to amplify the *siaD* gene for serogroups B, C, Y, and W135 and the *of2* of the *myb* gene for serogroup A [11]. Specimens testing positive for *H. influenzae* type b were confirmed by amplification of the *cap* gene [16]. PCR was performed in a Primus 96 thermocycler (MWG Biotech, Ebersberg, Germany). The detection threshold for PCR was 1–10 bacteria per assay, as shown by CSF samples spiked with serial 10-fold dilutions of reference strain suspensions of *N. meningitidis* serogroups A, B, C, Y and W135, *S. pneumoniae*, and *H. influenzae* b.

A “negative” CSF sample was negative by culture and PCR for *N. meningitidis*, *S. pneumoniae*, and *H. influenzae*. A “confirmed” CSF sample was a specimen that tested positive by culture and/or PCR for *N. meningitidis*, *S. pneumoniae*, or *H. influenzae*.

Development of RDTs for the Detection of Meningococcal PS Antigen

Anti-*N. meningitidis* monoclonal antibodies (Mabs) were developed at the Institut Pasteur (Paris, France). Biozzi BP/2 mice were immunized with four different PS conjugates (A, W135, C, and Y). Conventional fusion and ELISA screening of resulting hybridomas were carried out and IgG Mabs were selected on the basis of high specificity and affinity for purified A, W135, C, and Y PS. Conjugates and PS were kindly provided by Sanofi Pasteur. The selected Mabs were: K15–2 (anti-serogroup A IgG1, kappa chain); B6–1 (anti-serogroup C IgG1, kappa chain); L14–7 (anti-serogroup Y IgG2b, kappa chain); and C18–3 (anti-serogroup W135/Y IgG1, kappa chain). Although we obtained Mab D20–19, which is specific to serogroup W135 by ELISA, we did not use it because it cross-reacts with serogroup Y when used in immunochromatography. The four selected Mabs were conjugated to gold
particles by British Biocell International (Cardiff, UK), and four monovalent one-step vertical flow immunochromatography dipsticks (N. meningitidis serogroups A, C, Y, and W135/Y) were designed and optimized as previously described [17,18], with Acculuff polyester (Schleicher & Schuell Bioscience, Ecquevilly, France) used as the conjugate pad [19]. Homologous Mabs directed against serogroups A, C, Y, and W135/Y were sprayed onto the nitrocellulose at a high concentration of 2 μg per centimeter line, to give a specific capture line. As a control line for the capture of gold particles conjugated with mouse Mab, goat anti-mouse IgG was sprayed onto the nitrocellulose at a concentration of 0.8 μg/cm (ICN Biomedicals, Aurora, Ohio, United States). The hybridomas have been deposited at the Collection Nationale des Micro-organisms (Institut Pasteur, Paris, France) and are available upon request to Institut Pasteur.

Four monovalent dipsticks (serogroups A, W135/Y [i.e., detects both W135 and Y but does not distinguish between them], C, and Y) were optimized and preliminary tests carried out. They were assembled as two duplex dipsticks—RDT1 for A and W135/Y and RDT2 for C and Y (see Figure 1)—for evaluation by CERMES. The RDTs were stored at 4 °C in a moisture-proof bag until use. The test was carried out in 3 ml disposable plastic tubes at 25 °C in PBS, pH 7.2 was used. After incubation of the dipstick with its end in the sample for 10–15 min, the chromatographic result was recorded. A negative result consisted of a single upper pink control line, and a positive result consisted of two pink lines, the upper control line and the lower positive line.

Evaluation of Duplex RDTs
Sensitivity and specificity. The sensitivity and specificity of each RDT were assessed by one trained technician.

Reference isolates of N. meningitidis (serogroups A, B, C, W135, Y, and X), N. lactamica, S. pneumoniae, and H. influenzae b were obtained from the collection of strains of CERMES and from the WHO Collaborating Centre for meningococci (IMTTSA, Marseille, France) and stored at −80 °C in brain-heart infusion supplemented with 10% glycerol. The bacteria were cultured on blood agar at 37 °C with 5% CO₂ for 16 h. The colonies were suspended in PBS, adjusted to a concentration of 10⁸ cfu/ml (colony count of serial dilutions plated on blood agar), and heat-killed for 2 h at 60 °C. Numbers and reference strains tested for specificity were: 30 N. meningitidis of serogroup W135, 25 serogroup Y, 18 serogroup A, ten serogroup X, 11 serogroup B, seven serogroup C, nine N. lactamica, ten S. pneumoniae, and ten H. influenzae b. Numbers and strains tested for sensitivities were: ten N. meningitidis of serogroup A, 30 serogroup W135, 25 serogroup Y, and seven serogroup C.

CSF samples were collected in 2003–2005 from patients in Niger, before treatment, who were documented as suspected of having meningitis; these samples were tested by the reference standard tests (culture and/or multiplex PCR). These samples were stored at −20 °C until use. Numbers and strains tested for specificities were: 255 N. meningitidis of serogroup A, 48 serogroup W135, 11 serogroup X, 30 S. pneumoniae, 21 H. influenzae b, and 162 negative for N. meningitidis/S. pneumoniae/H. influenzae b; and for sensitivities

Figure 1. RDT Results by Serogroup
Results of RDT1 and RDT2 are shown for each N. meningitidis serogroup. DOI: 10.1371/journal.pmed.0030337.g001

N. meningitidis serogroup A
Negative
N. meningitidis serogroup C
N. meningitidis serogroup W135
N. meningitidis serogroup Y

255 N. meningitidis of serogroup A, 48 serogroup W135, and four serogroup Y. No CSF of serogroup C was available.

Cutoff, reproducibility, and shelf life. The detection limit (cutoff) of each RDT was determined on 10-fold dilutions of reference N. meningitidis PS from the National Institute for Biological Standards and Control (Hertfordshire, UK) for serogroup C code 38/730, serogroup A code 98/722, serogroup W135 code 01/426, and serogroup Y code 01/428, and for calibrated reference meningococcal strains from the Manchester Medical Microbiology Partnership (Manchester, UK) serogroup C code 11, serogroup A code 245594, and serogroup W135 code M01.240070 and from CERMES, serogroup Y code 477–03. Meningococcal strains were added to and diluted in pooled negative CSF samples.

The reproducibility of the cutoffs was assessed by testing, ten times simultaneously and using the same batch of RDTs, calibrated suspensions (10⁶ cfu/ml) of the reference meningococcal serogroups A, W135, C, and Y.

To predict the shelf-life of our RDTs, we used the accelerated stability method that consisted in storing the assays for a time at elevated temperature [20]. RDT1 and RDT2 were tested over a period of three weeks of exposure at high temperature of 60 °C on serial dilutions of PS serogroup A, W135, C and Y, twice per week. This accelerated stability method is equivalent to two years of actual storage time at room temperature (25 °C) [17]. In addition, as these RDTs are intended to be used in the field outside of air-conditioned settings, we compared the reliability of the tests performed at 25 °C (air-conditioned room) and 45 °C (incubator), simulating normal room temperature in the Sahel during the meningitis season.

Prospective Study
We compared the results obtained with PCR and RDT1 performed in a blind study by two different technicians, on 57 frozen CSF samples from patients with suspected meningitis. These samples were collected, before treatment, from patients in the Niamey and Maradi regions, from January 15th to February 11th 2005 and were received at the CERMES for aetiological diagnosis.

Statistics
The evaluation was performed according to the STARD (Standards for Reporting of Diagnostic Accuracy) for new assays [21].

We calculated the sensitivity (Se) of the RDTs, which is the
proportion of specimens with the target disorder in which the test result is positive; and the specificity (Sp), which is the proportion of specimens without the target disorder in which the test result is negative. The 95% confidence intervals (CIs) for Se and Sp were calculated [22].

We also calculated likelihood ratios (LR). The positive LR (LR+ = Se/[1 − Sp]) indicates how many times a positive result is more likely to be observed in specimens with the target disorder than in those without the target disorder. The negative LR (LR− = [1 − Se]/Sp) indicates how many times a negative result is more likely to be observed in specimens with the target disorder than in those without the target disorder. The test is more accurate the more LR differs from 1. LR+ above 10 and LR− below 0.1 were considered convincing diagnostic evidence [23]. The 95% CIs were calculated for LR+ and LR− [24]. LRs were not determined for a Se or Sp of 100%.

The diagnostic odds ratio (DOR), defined as the ratio of the odds of positive test results in specimens with the target disorder relative to the odds of positive test results in specimens without the target disorder, was calculated as follows [25]:

\[ \text{DOR} = \frac{\text{Se}/[1 - \text{Se}]}{[1 - \text{Sp}]/\text{Sp}} \] (1)

The DOR does not depend on prevalence and its value ranges from 0 to infinity, with higher values indicating better discriminatory test performance. The 95% CIs for DOR values were calculated [26].

The positive predictive value (PPV) represents the proportion of test-positive specimens that truly present the target disorder, while the negative predictive value (NPV) represents the proportion of test-negative specimens that truly do not present the target disorder:

\[ \text{PPV} = \frac{(\text{Prev} \times \text{Se})}{(\text{Prev} \times \text{Se}) + ([1 - \text{Prev}] \times [1 - \text{Sp}])} \] (2)

and

\[ \text{NPV} = \frac{([1 - \text{Prev}] \times \text{Sp})}{([1 - \text{Prev}] \times \text{Sp}) + [\text{Prev} \times (1 - \text{Se})]}. \] (3)

“Prev” is the prevalence of the target disorder in the population of specimens to which the test is applied. The 95% CIs for PPVs and NPVs were calculated [22].

Finally, we calculated the Cohen’s kappa (κ) statistic [27] to measure concordance between PCR and RDT in the prospective blind study. κ may range from 0 to 1, and a κ value higher than 0.8 is thought to reflecting almost perfect agreement [28]. The 95% CIs for κ were calculated according to a method described by Fleiss [29].

Ethical Aspects

All specimens were collected as part of the routine clinical management of patients, according to the national guidelines in Niger. Consequently, informed consent was not sought and approval from the national ethics committee was not required.

Results

The diagnostic accuracy (based on STARD criteria) of the RDTs was assessed from December 2004 to November 2005, and was completed in February and March 2006.

Cutoff and Reproducibility

As no monospecific Mab against W135 could be obtained, two duplex dipsticks were created: RDT1, for the detection of serogroups A and W135/Y, and RDT2, for the detection of serogroups C and Y and for discrimination between W135 and Y. The detection limits for the four serogroups were 1 ng PS/ml and 10^2 cfu/ml of CSF. The cutoffs could be reproduced ten times for each of the four serogroups tested (A, W135, C, and Y), using calibrated suspensions (10^5 cfu/ml) of reference strains.

No prozone phenomenon was observed with any of the RDTs at higher concentrations of PS (1 μg/ml) and bacteria (10^6 cfu/ml).

Sensitivities, Specificities, Likelihood Ratios, and Predictive Values

The sensitivities and specificities, with 95% CI, of the two RDTs with reference strains and documented CSF samples are summarized in Table 1. The sensitivity of RDT2 for CSF infected by serogroup C, a relatively rare serogroup in Africa, was not determined due to a lack of CSF samples but we were able to determine specificity. The specificity of the test for serogroup Y was 100%, but the sensitivity still must be accurately determined (all four CSF tested were positive).

For serogroup A identification, LR+ was 31.867 (95% CI, 16.1–63.1) and LR− was 0.065 (95% CI, 0.04–0.104), and the DOR was 492.9 (95% CI, 207.2–1,172.5). For serogroups W135 and Y, LR+ was 159.7 (95% CI, 51.7–493.3). It was not possible to calculate the other LRs and DORs because either their Se or their Sp was 100%.

The variations of NPV and PPV for the diagnosis of serogroups A and W135, according to prevalence, were determined using the Se and Sp for clinical CSF samples (Figure 2). To diagnose the four serogroups (A, W135, C, and Y), we propose an algorithm based on the combination in series of RDT1 and RDT2. Figure 1 shows the results obtained for both tests on each serogroup.

Shelf Life and Reliability

The results for RDT1 and RDT2 for the reference strains A, W135, and C were not affected by storage for 3 wk at 60 °C. For the serogroup Y, the test was stable for only 10 d at that temperature. RDT1 and RDT2 were equally accurate whether performed at ambient temperatures of 25 °C or 45 °C.

Comparative Prospective Study

PCR tests on 57 CSF samples from patients with suspected bacterial meningitis received for aetiological diagnosis showed that 20 samples contained N. meningitidis (17 of serogroup A, two serogroup W135, and two serogroup X), 16 S. pneumoniae, four H. influenzae b; 16 samples tested negative (Table 2). RDT1 identified 17 samples as positive for N. meningitidis serogroup A, and two as positive for W135/Y. There were two discordant results (serogroup A), giving an overall concordance level of 96.5% (55/57) between the two tests, and a Cohen’s κ coefficient of 0.92 (95% CI, 0.82–1.03).

Discussion

Because of the recent emergence of a new epidemic strain of N. meningitidis, serogroup W135, strengthening the capacity for epidemiologic and microbiologic surveillance and facil-
Faster mass vaccination are urgently needed for effective prevention and control of epidemic meningococcal disease in Africa. A rapid diagnostic assay for the identification of meningococci is also needed to ensure administration of the appropriate antimicrobial treatment, to improve case management.

When hybridoma cell lines were screened by ELISA, one specific anti-W135 Mab was obtained; however, when assessed by immunochromatography (very high concentration of Mab on the nitrocellulose), it cross-reacted with serogroup Y, so it was not used. Previous IgG3 anti-W135 Mab has been described by Tsang and colleagues [30], but its specificity was assessed by ELISA and not by immunochromatography. In the present study, we developed and validated on reference bacterial strains two duplex dipsticks. The first, RDT1, detects PS antigens specific to meningococcal serogroups A and W135/Y. The second, RDT2, detects serogroups C and Y.

### Table 1. Validation of RDT1 (Serogroups A and W135/Y) and RDT2 (Serogroups C and Y) for the Diagnosis of Meningococcal Meningitis

<table>
<thead>
<tr>
<th>Reference Samples Tested</th>
<th>Measure</th>
<th>RDT1</th>
<th>RDT2</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Serogroup A</td>
<td>Serogroups W135 and Y</td>
</tr>
<tr>
<td>Cultures (10^8 cfu/ml)</td>
<td>Specificity % (± 95% CI)</td>
<td>100 (96.6–100 (n = 112))</td>
<td>100 (95.1–100 (n = 75))</td>
</tr>
<tr>
<td></td>
<td>Sensitivity % (± 95% CI)</td>
<td>100 (82.4–100 (n = 18))</td>
<td>W135, 100 (88.6–100 (n = 30); Y, 100 (86.6–100 (n = 25))</td>
</tr>
<tr>
<td>CSF samples</td>
<td>Specificity % (± 95% CI)</td>
<td>97.1 (94.3–98.5 (n = 272))</td>
<td>99.4 (98.2–99.8 (n = 479))</td>
</tr>
<tr>
<td></td>
<td>Sensitivity % (± 95% CI)</td>
<td>93.8 (90.9–96.1 (n = 255))</td>
<td>W135, 100 (92.6–100 (n = 48) (LR+ 159.6 [51.7–493.3]); Y, 100 (51–100 (n = 4)) (LR+ 159.6 [51.7–493.3])</td>
</tr>
</tbody>
</table>

Sensitivities and specificities of RDT1 and RDT2 were assessed using cultures of collection strains or using reference CSF samples from meningitis patients. Number of strains or CSF tested is indicated by n. The sensitivity of the test for a given serogroup was calculated using homologous strains or CSF. The specificity of the test for a given serogroup was calculated using strains or CSF that are not the homologous strains or CSF. Consequently, the footnotes describe the different types of ‘‘nonhomologous’’ strains or CSF that were tested to determine specificity. The LR values are applicable to CSF samples, not strains. LR- cannot mathematically be calculated for a sensitivity of 100% (see mathematical formulas in Methods), such as for CSF serogroups W135 and Y.

DOI: 10.1371/journal.pmed.0030337.t001

### Figure 2. Predictive Values for *N. meningitidis* Diagnosis

PPVs and NPVs for the diagnosis of *N. meningitidis* serogroup A (A) and serogroups C and Y (B), according to prevalence of meningococcal meningitis. PPV is represented by the blue line with filled circles, and NPV by the red line with open circles. DOI: 10.1371/journal.pmed.0030337.g002

Table 2. Comparative Results of RDT1 and PCR for CSF Samples from Patients with Suspected Meningitis

<table>
<thead>
<tr>
<th>RDT1 (A and W135/Y)</th>
<th>Multiplex PCR (N. meningitidis, S. pneumoniae, H. influenzae)</th>
<th>Serogroup A</th>
<th>Serogroup W135/Y</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Negative</td>
<td></td>
<td>37</td>
<td>1</td>
<td>38</td>
</tr>
<tr>
<td>Serogroup A</td>
<td></td>
<td>1</td>
<td>16</td>
<td>17</td>
</tr>
<tr>
<td>Serogroup W135/Y</td>
<td></td>
<td>0</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td>38</td>
<td>17</td>
<td>57</td>
</tr>
</tbody>
</table>

Agreement between tests, 96.5% (55/57); Cohen’s kappa coefficient, 0.92 (0.82–1.03).

aClassified as “negative” for serogroup A or W135/Y. PCR results for these 37 CSF samples were 16 negative, two N. meningitidis X, 16 S. pneumoniae, and four H. influenzae b.

bNegative by RDT₁, weakly positive by PCR.

Strongly positive by RDT₁, noninterpretable by PCR (presence of inhibitors).

PCR and RDT₁ tests gave concordant results in 96.5% of cases in a blind comparative study performed by two technicians. The kappa coefficient obtained in this study was high (0.92), reflecting almost perfect agreement. The two discordant results corresponded to two serogroup A CSF specimens: one was negative with RDT₁ but weakly positive with PCR, and the second was strongly positive with RDT₁ but uninterpretable with PCR, due to the presence of inhibitors (no amplification of the positive control DNA). A large-scale study comparing PCR and RDTs is warranted in the future, since PCR detects DNA and RDTs detect PS antigen. Thus RDTs may actually be more sensitive than PCR in patients with prior antibiotic therapy, sample contamination, delays in processing, or presence of PCR inhibitors.

Our RDTs are easier to perform than currently available latex agglutination kits. They also give more rapid results and discriminate more accurately between serogroups Y and W135, using the second test (RDT₂) as a control. The negative and positive predictive values for the two main serogroups involved in outbreaks in the meningitis belt (A and W135) exceeded 95%, even for low prevalence of the disease. The RDTs merit evaluation (i) with other types of clinical samples (blood, urine) and on CSF samples of all serogroups from patients from developed countries; (ii) in operational field conditions of health care centres in Africa during epidemic and endemic periods; and (iii) on blood specimens of patients undergoing antibiotic therapy. These tests represent a major breakthrough for individual diagnosis and for surveillance of meningococcal diseases in the African meningitis belt that affect such a large proportion of meningitis patients in the world. The development of RDTs for serogroup B and X is ongoing, as well as for S. pneumoniae and H. influenzae b.

In order to make these RDTs available for supporting further field evaluation and epidemiological research, in-house small-scale production is being implemented in CERMES.

Supporting Information

Alternative Language Abstract S1. French Translation of the Abstract
Found at DOI: 10.1371/journal.pmed.0030337.sd001 (22 KB DOC).

Alternative Language Abstract S2. Spanish Translation of the Abstract
Found at DOI: 10.1371/journal.pmed.0030337.sd002 (24 KB DOC).
Acknowledgments

We thank Lydie Jaunasse, Souleymane Aouami, Fati Siddikou, and Amadou Moussa for technical support, and Jean Michel Alonso for helpful discussions. We would also like to thank Sanofi Pasteur for kindly providing the PS conjugates and the purified PS, and the WHOCC IMTSSA (Marseille, France) for providing reference meningococci strains.

Author contributions. S. Chanteau, P. Boisier, and F. Nato designed the project. S. Chanteau, P. Boisier, and F. Nato cowrote the manuscript. S. Chanteau, S. Djibo, and A.E. Mahamane contributed to the evaluation of the RDTs. S. Darrevelle and F. Nato contributed to the development of the monoclonal antibodies and the RDTs. S. Chanteau contributed to the coordination of the project. S. Chanteau was involved in optimizing the RDTs. P. Boisier carried out the statistical analysis of the data.

References
Editors’ Summary

Background: Bacterial meningitis, a potentially deadly infection of tissues that line the brain and spinal cord, affects over 1 million people each year. Patients with bacterial meningitis usually have fever, headache, and stiff neck, and may become unconscious and die if the disease is not treated within hours. Most cases of bacterial meningitis occur in Africa, particularly in the arid savannah region south of the Sahara known as the Sahel, where epidemic outbreaks of meningitis occur periodically. This region, also called the “meningitis belt,” extends from Senegal and adjacent coastal countries in West Africa across the continent to Ethiopia. Although most outbreaks tend to occur in the dry season, they differ in frequency in different areas of the meningitis belt, and may involve any of several kinds of bacteria. One of the major causes of epidemic meningitis is Neisseria meningitidis, a meningococcus bacterium that exists in several different groups. Group A has been a common cause of epidemic meningitis in Africa, and some outbreaks were due to group C. More recently, group W135 has emerged as an epidemic strain. In addition to prompt diagnosis and treatment of individual cases, effective public health strategies for controlling meningococcal meningitis include rapid identification of outbreaks and determination of the type of bacteria involved, followed by mass vaccination of people in the surrounding area without delay. Vaccines are chosen on the basis of the responsible meningococcal serogroup: either the inexpensive bivalent vaccine A/C or the expensive, less readily available trivalent vaccine A/C/W135. Before the advent of W135 as an epidemic clone, bivalent vaccine was applied in the meningitis belt without identification of the serogroup. With the appearance of the W135 strain in 2003, however, the determination of serogroup before vaccination is important to select an effective vaccine and avoid misspending of limited funds.

Why Was This Study Done? Because there are few laboratories in the affected countries and epidemiological surveillance systems are inadequate, it is difficult for health authorities to mount a rapid and effective vaccination campaign in response to an outbreak. In addition, because the two main bacteria (meningococcus and pneumococcus) that cause meningitis require different antibiotic treatments, it is important for doctors to find out quickly which bacteria is causing an individual case. The authors of this study wanted to develop a rapid test to determine whether a patient’s meningitis is caused by one of the four most common groups of meningococcus circulating in Africa. The test is done on the patient’s spinal fluid, which is obtained by a lumbar puncture (spinal tap) as part of the usual evaluation of a patient thought to have meningitis. The test uses two paper strips, also called dipsticks (one for groups A and W135/Y, and the other for groups C and Y), that can be placed in two separate tubes of the patient’s spinal fluid. After several minutes, the appearance of red lines on the dipsticks shows whether one of the four groups of meningococcus is present. The dipsticks can be produced in large quantities and relatively cheaply. The researchers showed that the test dipsticks are stable for weeks in hot weather, and are therefore practical for bedside use in resource-poor settings. They examined the test on stored spinal fluid from patients in Niger and found that the dipstick test was able to identify the correct group of meningococcus more than 95% of the time for the three groups represented in these specimens (the results were compared to a standard DNA test or culture that are highly accurate for identifying the type of bacteria present but much more complicated and expensive).

What Did the Researchers Do and Find? The researchers have developed a rapid test to determine whether a patient’s meningitis is caused by one of the four most common groups of meningococcus circulating in Africa. The test is done on the patient’s spinal fluid, which is obtained by a lumbar puncture (spinal tap) as part of the usual evaluation of a patient thought to have meningitis. The test uses two paper strips, also called dipsticks (one for groups A and W135/Y, and the other for groups C and Y), that can be placed in two separate tubes of the patient’s spinal fluid. After several minutes, the appearance of red lines on the dipsticks shows whether one of the four groups of meningococcus is present. The dipsticks can be produced in large quantities and relatively cheaply. The researchers showed that the test dipsticks are stable for weeks in hot weather, and are therefore practical for bedside use in resource-poor settings. They examined the test on stored spinal fluid from patients in Niger and found that the dipstick test was able to identify the correct group of meningococcus more than 95% of the time for the three groups represented in these specimens (the results were compared to a standard DNA test or culture that are highly accurate for identifying the type of bacteria present but much more complicated and expensive).

What Do These Findings Mean? The new dipstick test for meningococcal meningitis represents a major advance for health-care workers in remote locations affected by meningitis epidemics. This test can be stored without refrigeration and used at bedside in the hot temperatures typical of the African savannah during the meningitis season. The dipsticks are easier to use than currently available test kits, give more rapid results, and are more accurate in telling the difference between group Y and the increasingly important group W135. Further research is needed to determine whether the test can be used with other clinical specimens (such as blood or urine), and whether the test is dependable for detecting group C meningococcus, which is common in Europe but rare in Africa. Nonetheless, the dipstick test promises to be an important tool for guiding individual treatment decisions as well as public health actions, including vaccine selection, against the perennial threat of epidemic meningitis.

Additional Information. Please access these Web sites via the online version of this summary at http://dx.doi.org/10.1371/journal.pmed.0030337.

- World Health Organization fact sheet on meningococcal meningitis
- PATH Meningitis Vaccine Project
- US Centers for Disease Control and Prevention page on meningococcal disease